Symbol="IKT"
AssetType="Common Stock"
Name="Inhibikase TherapeuticsÂ Inc"
Description="Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia."
CIK="1750149"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="11285000"
EBITDA="-18121884"
PERatio="None"
PEGRatio="None"
BookValue="3.679"
DividendPerShare="0"
DividendYield="0"
EPS="-4.03"
RevenuePerShareTTM="0.055"
ProfitMargin="0"
OperatingMarginTTM="-78.5"
ReturnOnAssetsTTM="-0.439"
ReturnOnEquityTTM="-0.777"
RevenueTTM="251790"
GrossProfitTTM="-8258499"
DilutedEPSTTM="-4.03"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="16.77"
AnalystTargetPrice="27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="219.63"
PriceToBookRatio="0.492"
EVToRevenue="2.748"
EVToEBITDA="0.733"
Beta="0.747"
num_52WeekHigh="6.94"
num_52WeekLow="2"
num_50DayMovingAverage="2.842"
num_200DayMovingAverage="3.564"
SharesOutstanding="5300000"
DividendDate="None"
ExDividendDate="None"
symbol="IKT"
open="2.10"
high="2.15"
low="2.00"
price="2.11"
volume="46548.00"
latest_trading_day="2023-08-25"
previous_close="2.12"
change="-0.01"
change_percent="-0.4717%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="95"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="5"
Volume_recent_avg="87474"
Change_recent_avg="-0.01"
Delta_recent_avg="0.13"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.4"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="5"
Aroon_momentum_negative="95"
image_negative_thumbnail_id_1="1130"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0163.jpeg"
image_negative_thumbnail_id_2="1153"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0186.jpeg"
image_neutral_thumbnail_id_1="544"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0055.jpeg"
image_neutral_thumbnail_id_2="556"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0043.jpeg"
image_positive_thumbnail_id_1="1004"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0166.jpeg"
image_positive_thumbnail_id_2="976"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0138.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
